Ectonucleotidases as bridge between the ATP and adenosine world: reflections on Geoffrey Burnstock

Jürgen Schrader

Received: 28 January 2022 / Accepted: 4 April 2022 / Published online: 6 May 2022
© The Author(s) 2022

Abstract
Historically, mainly by the work of Robert Berne, extracellular adenosine was the first purine compound recognized as an important signaling molecule linking energy metabolism to function by acting on membrane bound receptors. Geoffrey Burnstock by his vision and endurance pioneered the idea that cells release ATP that also acts as an extracellular signaling molecule under many physiological and pathophysiological circumstances. Only later, it was appreciated that extracellular ATP and adenosine are metabolically linked by the activity of several ectoenzymes which critically determine the concentrations of these purines at their respective receptors. In this brief review, I will report some personal recollections on Geoffrey Burnstock and his impressive personality. In addition, I will give a brief overview on our present knowledge of extracellular purine metabolism and its control and will address some still open issues.

Keywords
ATP · Adenosine · Ectoenzymes · CD73 · Metabolism · Burnstock

Jürgen Schrader studied Medicine and graduated at the University of Freiburg, Germany in 1969. He was holding the chair of Cardiovascular Physiology at the University of Düsseldorf from 1983–2011. Presently he is heading the Department of Molecular Cardiology in Düsseldorf. He is member of the Royal Academy of Pharmacy, Spain, and the German National Academy of Sciences, Leopoldina. His research interest includes metabolic cardiovascular regulation and purinergic signaling.

Introduction
Jeoffrey Burnstock (1929–2020) entered my scientific life very early in my career. After a postdoc with Robert M. Berne (1918–2001) in Charlottesville in the early 1970s, — Berne’s lab was leading adenosine research in these times — I came across Jeoff’s now famous 1972 review in Pharmacological Reviews on Purinergic Nerves, proposing a central role for extracellular ATP [1]. I still remember that even after careful reading, I found Jeoff’s proposal not fully convincing, since the evidence was indirect and released ATP has not been directly measured. The adenosine field at that time was much more advanced and there were analytical techniques available to quantify this nucleoside and link its concentration to function. Reliably measuring ATP has been a major task in the years to follow since it was and still is difficult to differentiate analytically between lytic ATP release from dying cells and specific ATP release mechanisms. In addition, Berne’s adenosine hypothesis for metabolic coronary flow regulation at that time assumed that most of the adenosine during hypoxia is formed within the cell and then diffuses into extracellular space to become functionally active. The history of adenosine research and Berne’s contribution was elegantly reviewed by Ray Olsson [2]. At that time, there was conceptually no need for extracellular
ATP being a precursor of adenosine at least in the cardiovascular field.

This perspective fundamentally changed in the 1990s when it was discovered, mainly by the work of Herbert Zimmermann and Gennady Yegutkin, that there are various ectoenzymes present at the outer cell surface which can effectively break down extracellular ATP to adenosine [3, 4]. This pathway did not require hypoxia, but was it also functionally important? Knockout of CD39 by the Robson lab [5] and CD73 in my [6] and Linda Thompson’s lab [7] clearly showed that the ectoenzyme pathway was indeed quantitatively important and resulted in major cardiovascular phenotypes under stressed conditions. Metabolically speaking, there must have been a continuous cellular release of ATP which provides AMP, the substrate of CD73. Jeoffrey Burnstock was proven right!

How it all began

The first of a series of conferences which brought the ATP and adenosine world together was organized by Hans Baer and George Drummond in 1978 in Banff, Canada, and was entitled “Physiologic and regulatory functions of adenosine and adenine nucleotides” [8]. This meeting was intellectually exiting and marked the point in time when the field took off. Great outdoor activities facilitated the exchange ideas and getting to know the participants coming from chemistry, pharmacology, and physiology. Figure 1 shows some of the participants of the Banff conference on a boat trip. Interestingly, the ATP group with Jeoff Burnstock standing up was sitting on the front side of the boat, while the adenosine group occupied the other side. This somewhat reflects that historically, there used to be — for quite some time — a distinct ATP world and adenosine world, and the proponents of each acted sometimes like enemy brothers, on meetings and otherwise.

In a broader view, however, the two systems are part of an exiting regulatory network in living tissue that is connected by ectoenzymes. It soon became obvious that it is the enzymatic activity of these ectoenzymes that critically determines whether cells of a given tissue are exposed to a predominant ATP or adenosine environment. Clearly, extracellular purine metabolism is very dynamic and is controlled by many variables. With extracellular ATP and adenosine enzymatically interconnected, nature has developed a complex but highly interesting regulatory system which we are only beginning to understand.

Jeoff the mover

Jeoff certainly was a man with great vision and particularly his enthusiasm for purinergic signaling was contagious and has stimulated many talented researches to enter the field. For example, he collaborated with Eric Barnard...
(1927–2018), an eminent molecular biologist in London, and they both were the first to characterize and clone G-protein-coupled receptor for ATP [9]. Since there are receptors for ATP, there must be extracellular ATP and this made the ATP signaling circle complete. Jeoff’s original hypothesis was now on firm molecular grounds.

Jeoff’s ability to infuse enthusiasm was with him from his early school time. In a personal reflection on his live during one of his last plenary lectures, he told the story that during his time at school, he was very keen on table tennis. After a while he managed that not only his class but also the entire school was involved in regular table tennis tournaments. This was only put to an end, after the director of the school declared that there are other important sports aside of table tennis.

One of Geoff’s strength, as I remember him, was his ability to integrate the many publications in the purinergic signaling field into a coherent picture. He wanted to understand how purines in a living system really worked and whether one could therapeutically interfere. To this end, he knew the relevant literature very well and was a master in presenting it! I still remember receiving — in the pre-electronic area — regular postcards from him with request for a reprint. Geoff wrote many excellent reviews. Well cited is his review on “Receptors for purines and pyrimidines” [10] with over 1000 references. His last review on the therapeutic developments in purinergic signaling, published in 2017, is another impressive example in this respect [11]. With more than 900 references, he covers the potential relevance of purinergic signaling in all disease states so far investigated. This paper provides important insights and will be a valuable literature resource for the future.

Where do we presently stand?

We now know that ATP and adenosine are metabolically well interconnected by several ectonucleotidases (Fig. 2) which play an important role in purinergic signaling by P1 and P2 receptors. Several recent reviews competently summarize our present knowledge on the individual enzymes

![Fig. 2](image-url)
involved [12, 13], their role in acute and chronic inflammation [14] in human diseases [15], including history of ectonucleotidases [16], and potential checkpoint inhibitors in cancer treatment [17].

Figure 2 depicts our present view on the major ectoenzymes involved and corresponding metabolites which constitute a metabolic pathway. In the following, I will briefly address some general regulatory principles of metabolic control which also apply to this extracellular pathway from ATP to adenosine. The conceptional basis for regulation in metabolic pathways was laid by the Oxford biochemist Eric Arthur Newsholme (1935–2011) [18] and was more recently applied to state-of-the-art studies [19]. By using thermodynamic concepts, Newsholme postulated that accurate measurements of the concentrations of the intermediary substrates and products as well as product/substrate ratios are required to characterize the nature of the reaction catalyzed by each enzyme. Such measurements are feasible in isolated cells in culture but are difficult in intact tissue since the assessment of the composition of the extracellular fluid space is technically demanding. In the case of ATP, Di Virgilio and colleagues [20] have elegantly engineered a chimeric plasma membrane luciferase (pmeLUC), that is targeted to the outer plasma membrane and permits sensitive interstitial ATP measurements [20]. Comparable sensors for adenosine are presently not available and at best rely on electrochemical microsensors [21, 22] and microdialysis [23]. In the future, it would be highly desirable to be able to non-invasively quantify extracellular ATP, ADP, and adenosine in a complex tissue context, since it is finally the concentration of these purine compounds which elicits signaling at the respective P1 and P2 receptors.

Each metabolic pathway starts with a flux-generating step and ends with the loss of the products or may constitute the start of another metabolic pathway. Clearly, the ectonucleotidase cascade is initiated by the cellular release ATP and NAD by various mechanisms [24]. The actual purine concentration is determined by the rate of ATP and NAD degradation. Similar consideration apply to adenosine, the concentration of which under normoxia is critically determined by two kinetic parameters: rate of production from AMP as compared to the rate of adenosine removal by reuptake into the cell (salvage pathway) [25] and deamination to inosine [26]. Aside of the activity of CD73, also the substrate concentration of AMP matters. Theoretically, it is possible that despite increased CD73 activity, this might go along with unchanged or even decreased adenosine levels, whenever the rate of deamination and cellular reuptake is equal or exceeds adenosine production! Whether such a metabolic situation is biologically realized is presently not known.

From these considerations, it is evident that it may be misleading to extrapolate — as frequently done — from measurements of enhanced CD73 at the gene or protein level to elevated adenosine levels in respective tissues. This the more, since CD73 activity can be inhibited by NAD-riboylation [27] which can explain the profound inhibition of CD73-dependent formation of anti-inflammatory adenosine in B cells of SLE patients recently reported by us [28, 29]. Again, this calls for reliable measurements of ATP and adenosine in the interstitial space of organs and tumors.

Under normoxic conditions, most of the extracellular adenosine is derived by the concerted action of the various ectonucleotidases such as CD39, CD38, and ENNP1 (Fig. 2). In tumors, ENPP1 was recently shown to also selectively degrade extracellular cGAMP, an immune-stimulatory metabolite whose breakdown product is adenosine [30]. The extracellular adenosine concentration normally exceeds intracellular adenosine so that the flux is from outside to inside, parenchymal cell representing a sink, not a source, for adenosine [31]. Under hypoxic conditions, however, the situation dramatically changes in that the gradient is reversed and adenosine accumulates in a PO2-dependent manner [32]. The metabolic basis for this effect is the existence of an intracellular “futile cycle” between AMP and adenosine involving cytosolic 5′-nucleotidase and adenosine kinase. Substrate cycles as efficient mechanisms to improve control sensitivity have already been discussed by Newsholme [18]. The biological function of this high turnover AMP-adenosine metabolic cycle is that inhibition of adenosine kinase activity can substantially augment intracellular adenosine thereby steepening the gradient to the extracellular space. Interestingly, hypoxia induces inhibition of adenosine kinase whereby small changes in hypoxia-induced free AMP are converted into a major rise in adenosine [33]. Since the metabolic cycle between AMP and adenosine is linked to the transmethylation pathway from SAM to SAH (Fig. 2), it is not surprising that adenosine kinase appears also to be important in determining the global methylation status of DNA, thereby contributing to epigenomic regulation [34]. Taken together, extracellular adenosine formed by hypoxia is most likely derived from both the extracellular degradation of ATP and the direct cellular export by nucleoside transporters. Use of highly specific ecto-ATPase inhibitor can differentiate between these two possibilities [35]. Inhibition of adenosine kinase is still an elegant means to augment adenosine under normoxic conditions.

**What comes next?**

Given the complexities of extracellular purine metabolism, future studies on the dynamics of this pathway might involve the application of isotopically labelled tracers
combined with NMR and mass spectrometry, techniques that were successfully applied in the past to metabolic pathways in various organs [36]. Challenges persist as to the accurate estimation of substrate concentrations and flux rates from stable-isotope tracers. While the principles of metabolic regulation are similar, organ/cell-specific differences are likely to exist and need to be considered. With the advent of single cell transcriptomics and spatial proteomics, we have now to integrate the ATP release from various cellular sources which finally determine in an intact tissue the interstitial purine concentration to which the ATP and adenosine receptors are exposed to. A better understanding on the dynamics of extracellular ATP degradation to adenosine in vivo will certainly provide a rational basis for the development of novel therapeutic strategies.

Acknowledgements I would like to thank Dr. Julia Hesse, Duesseldorf, for fruitful discussion and help in designing Figure 1. Many thanks also to Dr. Christine Des Rosiers, Montreal Heart Institute, for valuable advice and feedback on this manuscript.

Funding Open Access funding enabled and organized by Projekt DEAL. Juergen Schrader was supported by a grant of the German Research Council (DFG, SFB1116, project identifier: 236177352) and the Cardiovascular Research Institute Duesseldorf (CARDI).

Data availability Not applicable.

Declarations

Conflicts of interest The author has no conflict of interest to declare.

Ethical approval Not applicable.

Consent to participate Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Burnstock G (1972) Purinergic nerves. Pharmacol Rev 24:509–581
2. Olsson RA (2003) Robert Berne: his place in the history of purine research. Drug Dev Res 58:296–301
3. Zimmermann H (2000) Extracellular metabolism of ATP and other nucleotides. Naunyn-Schmied Arch Pharmacol 362:299–309
4. Yegutkin GG (2008) Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1783, 673–694.
5. Enjoji K et al (1999) Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 5:1010–1017
6. Koszalka P et al (2004) Targeted disruption of cd73/ecto-5’-nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ Res 95:814–821
7. Thompson LF et al (2004) Crucial role for ecto-5’-nucleotidase (CD73) in vascular leakage during hypoxia. J Exp Med 200:1395–1405
8. Baer HP, Drummond GI, Bartlett V, Eds. (1979) Physiological and regulatory functions of adenosine and adenine nucleotides: based on proceedings of a conference held in Banff, Alberta, Canada, June 11 - 16, 1978 (Raven Press, 1979)
9. Simon J, Webb TE, King BF, Burnstock G, Barnard EA (1995) Characterisation of a recombinant P2Y purinoceptor. Eur J Pharmacol 291:281–289
10. Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50:413–492
11. Burnstock G (2017) Purinergic signalling: therapeutic developments. Front Pharmacol, 8.
12. Zimmermann H, Zebisch M, Sträter N (2012) Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal 8:437–502
13. Yegutkin GG (2014) Enzymes involved in metabolism of extracellular nucleotides and nucleosides: functional implications and measurement of activities. Crit Rev Biochem Mol Biol 49:473–497
14. Giuliani AL, Sarti AC, Di Virgilio F (2021) Ectonucleotidases in acute and chronic inflammation. Front Pharmacol 11:619458
15. Huang Z et al (2021) From purines to purinergic signalling: molecular functions and human diseases. Sig Transduct Target Ther 6:162
16. Zimmermann H (2021) History of ectonucleotidases and their role in purinergic signaling. Biochem Pharmacol 187:114322
17. Boison D, Yegutkin GG (2019) Adenosine metabolism: emerging concepts for cancer therapy. Cancer Cell 36:582–596
18. E. A. Newsholme, C. Start, Regulation in metabolism (Wiley, 1973).
19. Curi R et al (2016) Regulatory principles in metabolism—then and now. Biochem J 473:1845–1857
20. Pellegratti P, Falzoni S, Pinton P, Rizzuto R, Di Virgilio F (2005) A novel recombinant plasma membrane-targeted luciferase reveals a new pathway for ATP secretion. MBoC 16:3659–3665
21. Zhang D et al (2019) Electrochemical aptamer-based microsensor for real-time monitoring of adenosine in vivo. Anal Chim Acta 1076:55–63
22. Dale N (2021) Real-time measurement of adenosine and ATP release in the central nervous system. Purinergic Signal 17:109–115
23. Ramakers B et al (2008) Measurement of the endogenous adenosine concentration in humans in vivo: methodological considerations. CDM 9:679–685
24. Kepp O, et al. (2021) ATP and cancer immunosurveillance. EMBO J, 40
25. Pastor-Anglada M, Pérez-Torres S (2018) Who is who in adenosine transport. Front Pharmacol 9:627
26. Kutryb-Zajac B, Mierzejewska P, Slominska EM, Smoleniski RT (2020) Therapeutic perspectives of adenosine deaminase inhibition in cardiovascular diseases. Molecules 25:4652
27. Leutert M et al (2021) Identification of the mouse T cell ADP-ribosylome uncovers ARTC2.2 mediated regulation of CD73 by ADP-ribosylation. Front Immunol 12:703719
28. Hesse J et al (2021) Profound inhibition of CD73-dependent formation of anti-inflammatory adenosine in B cells of SLE patients. EBioMedicine 73:103616
29. Hesse J et al. (2021) Mono-ADP-ribosylation sites of human CD73 inhibit its adenosine-generating enzymatic activity. Purinergic Signal. https://doi.org/10.1007/s11302-021-09832-4 (January 5, 2022).
30. Li J et al (2021) Metastasis and immune evasion from extracellular cGAMP hydrolysis. Cancer Discov 11:1212–1227
31. Deussen A, Stappert M, Schäfer S, Kelm M (1999) Quantification of extracellular and intracellular adenosine production: understanding the transmembranous concentration gradient. Circulation 99:2041–2047
32. Deussen A, Schrader J (1991) Cardiac adenosine production is linked to myocardial pO2. J Mol Cell Cardiol 23:495–504
33. Decking UK, Schlieper G, Kroll K, Schrader J (1997) Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. Circ Res 81:154–164
34. Murugan M et al (2021) Adenosine kinase: an epigenetic modulator in development and disease. Neurochem Int 147:105054
35. Melani A et al (2012) Ecto-ATPase inhibition: ATP and adenosine release under physiological and ischemic in vivo conditions in the rat striatum. Exp Neurol 233:193–204
36. Karlstaedt A (2021) Stable isotopes for tracing cardiac metabolism in diseases. Front Cardiovasc Med 8:734364

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.